A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

开始日期2023-10-11

申办/合作机构

Sling Therapeutics, Inc.

NCT05276063

/ Active, not recruiting临床2/3期

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

开始日期2022-07-01

申办/合作机构

Sling Therapeutics, Inc.

NCT02057380

/ Completed临床2期

A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.

开始日期2014-04-16

申办/合作机构

Astellas Pharma Global Development, Inc.

100 项与林西替尼相关的临床结果

登录后查看更多信息

100 项与林西替尼相关的转化医学

登录后查看更多信息

100 项与林西替尼相关的专利（医药）

登录后查看更多信息

380

项与林西替尼相关的文献（医药）

2025-05-01·INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY

The role of insulin receptor InR in photoperiod-regulated reproductive diapause of Chrysoperla nipponensis

Article

作者: Kang, Zhiwei ; Xu, Minghui ; Xu, Yongyu ; Wang, Xiao ; Kabissa, Jeremiah Joe ; Kong, Xue ; Chen, Zhenzhen ; Zhong, Shaofeng ; Li, Dandan

Insects usually diapause, a process regulated by hormonal signals as an adaptive mechanism developed through long-term evolution to survive unfavorable environmental conditions. Chrysoperla nipponensis is classified as a photoperiod-sensitive insect. Treatments with short-day (SD) and long-day (LD) conditions have distinct effects on ovarian development and lipid accumulation in adults, with SD condition inducing diapause. Injecting bovine insulin promoted ovarian development and egg formation in diapause females, while injecting insulin receptor induced diapause-like traits in reproductive females. This study investigate the biological function of insulin signaling in the reproductive diapause of females of C. nipponensis. Under SD treatment the mRNA expression level of InR1 and InR2, as well as the protein expression level of InR1 were significantly reduced. This reduction led to stagnant ovarian development, increased adipose tissue mass, and a significant rise in triglyceride (TG) content. Silencing InR1 under LD conditions resulted in halted ovarian development and enhanced lipid accumulation, with the expression levels of Akt, Kr-h1, and Vg significantly decreased mirroring those observed under SD conditions. Interestingly, silencing InR2 under LD condition did not affect ovarian development. Furthermore, transcriptome analysis identified six genes (Akt, PkN, Skp2, CycB3, BTrC, and AurkA) associated with reproductive regulation and eight genes (FadΔ11, EchA, EcI, Ugts (2A3, 1-9), AR, Gpdh and Cbr) linked to lipid metabolism, all of which are involved in InR1 mediated regulation of C. nipponensis reproduction.

2025-05-01·JOURNAL OF ETHNOPHARMACOLOGY

IGF-1 signaling pathway activation promotes axonal regeneration and repair: A mechanism study on catalpol-induced functional recovery after ischemic stroke

Article

作者: Liu, Yan ; Mei, Siqi ; Wu, Dan ; Li, Wenlei ; Xu, Xinyu ; Wu, Yang ; Hua, Hao ; Yan, Xiaohui ; Wu, Minghua ; Li, Li ; Zhu, Jian

ETHNOPHARMACOLOGICAL RELEVANCE:

In traditional Chinese Medicine (TCM) theory, there is a concept of "tonifying the kidney and generating marrow, and marrow enriches and nourishes the brain ", which believes that tonifying the kidney and generating marrow can promote brain marrow repair and neurological function recovery. This theoretical framework has been substantiated by multiple modern medical studies. Catalpol, a bioactive iridoid glycoside extracted from Rehmannia glutinosa (Gaertn.) DC. has been traditionally employed in TCM for "kidney tonification, marrow generation, and brain nourishment". Regenerative remodeling of corticospinal tracts (CST) mediated by axonal regeneration, collateral formation, and neural network reconstruction is critical for neurological recovery after ischemic stroke. As the primary active component of Rehmannia glutinosa, catalpol may manifest the traditional medicinal effects of promoting neurological recovery through modern neuroregenerative mechanisms.

AIM OF THE STUDY:

To verify whether catalpol promotes neurological recovery after ischemic stroke and elucidate its underlying mechanisms.

METHODS:

Potential therapeutic targets of catalpol were first identified through network pharmacology coupled with cellular thermal shift assay (CETSA) validation. In vivo experiments utilized a photothrombotic (PT) stroke mouse model, in which catalpol's effects on neurological recovery were quantitatively assessed using behavioral tests. Axonal regeneration dynamics and IGF-1 pathway activation were systematically evaluated through functional magnetic resonance imaging (fMRI) for CST remodeling, growth-associated protein 43 (GAP43) and myelin basic protein (MBP) immunofluorescence for axonal sprouting quantification, and Western blotting for insulin-like growth factor-1 (IGF-1), insulin-like growth factor-1 receptor (IGF-1R), mammalian target of rapamycin (mTOR), and GAP43 expression profiling. Complementary in vitro studies employing oxygen-glucose deprived (OGD) neurons demonstrated catalpol's effects on proliferation, migration and axonal growth using Cell Counting Kit-8 (CCK-8), immunofluorescence, scratch wound assay and Western Blot. Mechanistic specificity was confirmed through pharmacological IGF-1R inhibition with linsitinib.

RESULTS:

Catalpol was found to directly bind to IGF-1R, as evidenced by molecular docking (binding energy: -6.5 kcal/mol) and CETSA (ΔTm = 4.38 °C). In vivo, catalpol treatment significantly improved motor and sensory recovery in post-stroke mice, reducing error rates in irregular ladder walking (P = 0.014 vs. model) and shortening sticker removal times (P = 0.0043 vs. model), effects that were abolished by IGF-1R inhibition with linsitinib. Diffusion tensor imaging revealed enhanced fractional anisotropy (FA) values in corticospinal tract regions (e.g., dorsal fornix: P = 0.0496), alongside increased axonal markers GAP43 and MBP expression (P < 0.01) in peri-infarct tissues. In vitro, catalpol rescued oxygen-glucose deprivation (OGD)-induced neuronal damage, promoting SH-SY5Y cell viability (P < 0.01), neurite elongation (P < 0.0001), and scratch wound closure (P < 0.001). Mechanistically, catalpol upregulated IGF-1R phosphorylation, activated mTOR signaling, and suppressed phosphatase and tensin homolog deleted on chromosome ten (PTEN), thereby elevating GAP43, osteopontin (OPN), and p-S6 levels (P < 0.05-0.001). Co-treatment with linsitinib negated these effects, confirming the dependency on IGF-1R/mTOR/PTEN axis. These findings establish catalpol as a multimodal neuroregenerative agent targeting IGF-1 signaling to drive axonal repair and functional recovery post-stroke.

CONCLUSION:

Our research elucidates that catalpol improves neurological recovery in ischemic stroke by regulating the IGF-1 signaling pathway to promote axonal regenerative repair, providing a new perspective for addressing the challenge of functional recovery in ischemic stroke.

2025-04-07·ONCOGENE

Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma

Article

作者: Fujita, Naoya ; Funauchi, Yuki ; Takemoto, Ai ; Huang, Tianyi ; Takami, Miho ; Sakata, Seiji ; Takagi, Satoshi ; Nakajima, Mikako ; Katayama, Ryohei ; Koike, Sumie ; Sugiura, Yoshiya ; Saito, Masanori ; Baba, Satoko ; Ae, Keisuke ; Takeuchi, Kengo ; Seto, Yosuke

Osteosarcoma (OS) is a primary malignant bone tumor primarily affecting children and adolescents. The lack of progress in drug development for OS is partly due to unidentified actionable oncogenic drivers common to OS. In this study, we demonstrate that copy number gains of MCL1 frequently occur in OS, leading to vulnerability to therapies based on Mcl-1 inhibitors. Fluorescence in situ hybridization analysis of 41 specimens revealed MCL1 amplification in 46.3% of patients with OS. Genetic inhibition of MCL1 induced significant apoptosis in MCL1-amplified OS cells, and the pharmacological efficacy of Mcl-1 inhibitors was correlated with MCL1 copy numbers. Chromosome 1q21.2-3 region, where MCL1 is located, contains multiple genes related to the IGF-1R/PI3K pathway, including PIP5K1A, TARS2, OUTD7B, and ENSA, which also showed increased copy numbers in MCL1-amplified OS cells. Furthermore, combining Mcl-1 inhibitors with IGF-1R inhibitors resulted in synergistic cell death by overcoming drug tolerance conferred by the activation of IGF signaling and suppressed tumor growth in MCL1-amplified OS xenograft models. These results suggest that genomic amplification of MCL1 in the 1q21.2-3 region, which occurred in approximately half of OS patients, may serve as a predictive biomarker for the combination therapy with an Mcl-1 inhibitor and an IGF1R inhibitor.

项与林西替尼相关的新闻（医药）

2025-01-14

·FierceBiotech

Sling\'s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3

Convenience is one area Sling Therapeutics may have an edge over the incumbent in thyroid eye disease. \n Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) trial, teeing the biotech up to run a confirmatory study of its ex-Astellas asset. But a cross-trial comparison suggests Amgen’s blockbuster may have the advantage on the efficacy front.Astellas studied the small-molecule IGF-1R inhibitor linsitinib as a cancer treatment. However, with the anti-IGF-1R antibody Tepezza showing the benefits of targeting the receptor in TED, Sling spied a chance to use linsitinib in the eye disease. The biotech launched with $35 million to run a phase 2b trial in TED, a complication of Graves’ disease that causes the eyes to bulge, in 2022.About 18 months later, Sling has evidence linsitinib works in TED. Investigators randomized 90 patients to receive one of two doses of linsitinib or placebo. After 24 weeks, 52% of people on the high dose had a big enough reduction in eye bulging to meet the response criteria.The response rate was significantly higher than in the placebo group, causing the high dose to achieve the primary endpoint. Sling made no mention of the performance of the low dose. The biotech is now preparing to start a confirmatory phase 3 trial this year. Horizon Therapeutics, which brought Tepezza to market before selling up to Amgen, reported a higher response rate in its phase 3 program. After eight infusions across 24 weeks, the response rates in the two Tepezza trials were (PDF) 71% and 83%. Cross-trial comparisons can be misleading, but the available data suggest Sling may need to focus on areas other than efficacy to compete.Convenience is one area Sling may have an edge over the incumbent. Tepezza patients receive 60- to 90-minute infusions every three weeks. Linsitinib is taken orally twice a day. Amgen began a phase 3 trial of a subcutaneous formulation of Tepezza last year, positioning it to potentially free patients from lengthy infusions in the future.Safety and tolerability is another potential battleground. In Tepezza’s phase 3 program, 10% of patients on the drug developed hearing impairment, a catch-all term for conditions such as deafness and tinnitus. Sling said no drug-related hearing impairment was reported in its trial, although there was one unrelated report, and the placebo-adjusted tinnitus rate was 0%. Hyperglycemia was rarer than for Tepezza, too.Sling saw elevated liver enzymes, but they resolved quickly and caused no signs of drug-induced injury, leading the biotech to conclude linsitinib was well tolerated. The planned phase 3 trial will shed more light on the molecule’s safety and efficacy profile and potentially position Sling to challenge Amgen for the TED market.

$Sling\'s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3$

临床3期临床结果临床2期

2025-01-14

·PRNewswire

Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease

- Linsitinib is the first and only oral small molecule therapy to establish statistical and clinical significance in Thyroid Eye Disease (TED) - Phase 2b/3 LIDS trial met primary endpoint of proptosis reduction with statistical significance at 150mg BID dose - Linsitinib was well-tolerated particularly in IGF-1R areas of interest such as hearing impairment, glycemic changes, and menstrual cycle changes - Confirmatory Phase 3 trial on track to commence in 2025 ANN ARBOR, Mich., Jan. 14, 2025 /PRNewswire/ -- Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED. Linsitinib, Sling's lead product candidate, is a convenient oral small molecule, taken twice-daily, in clinical development for TED. Linsitinib works by inhibiting the validated IGF-1R target and has an established safety profile through treatment of more than 900 patients across fifteen clinical trials in multiple disease areas. "The positive data from this trial establish the clinical significance of linsitinib and represent the first ever successful clinical trial of an oral small molecule for the treatment of TED," said Ryan Zeidan, Ph.D., President and Chief Executive Officer of Sling Therapeutics. "We believe linsitinib can be a potential new treatment option that could enable a broader number of physicians across multiple therapeutic disciplines to treat patients diagnosed with TED. We are excited to continue our clinical program and are on track to initiate our confirmatory Phase 3 registrational trial later this year." Trial Overview and Topline Results The LIDS Phase 2b/3, randomized, double-masked, placebo-controlled study was designed to evaluate the safety, pharmacokinetics, and efficacy of linsitinib in patients with active, moderate to severe TED. The primary endpoint of the study was the percentage of subjects who were proptosis responders at week 24, defined as at least a two-millimeter reduction in proptosis from baseline. The LIDS trial enrolled 90 patients who were randomized 1:1:1 and received either linsitinib 150mg BID, linsitinib 75mg BID, or placebo for 24 weeks. The trial was conducted globally at 35 sites in five countries. The LIDS trial met its primary endpoint with statistical significance for the 150mg BID dose. Linsitinib in this trial validated the safety profile seen in the prior oncology studies and importantly demonstrated a favorable safety profile on key adverse events (AEs) of interest for the IGF-1R target such as hearing impairment, hyperglycemia, and menstrual cycle changes. Additionally, no QTc prolongation was observed in any patient with rigorous ECG monitoring throughout the study. Key Topline Data: Statistically Significant Proptosis Responder Rate (PRR): PRR was statistically significant and clinically meaningful at the 150mg BID dose, with a PRR of 52% (p = 0.01) at Week 24. Consistent Safety Data, No Drug-Related Hearing Impairments: Linsitinib was well-tolerated and consistent with the safety profile of the previous 15 linsitinib clinical trials, which now includes more than 900 patients in multiple disease areas. Key AE data from the 150mg BID arm include: No drug-related hearing impairment reported (1 unrelated report out of 29 patients) 0% tinnitus placebo-adjusted rate 3% rate of hyperglycemia (1 report out of 29 patients with no intervention required) 0% menstrual cycle changes reported Treatment emergent AEs greater than or equal to 10%: diarrhea (20.7%), headache (20.7%), nausea (20.7%), fatigue (17.2%), ALT increase (17.2%), hyperhidrosis (13.8%), AST increase (10.3%), and muscle spasms (10.3%) Hepatic transaminases were all quickly resolved and not associated with any elevations of total bilirubin, alkaline phosphatase, hepatic dysfunction, or other signs or symptoms of drug-induced liver injury The majority of AEs were either mild or moderate, reversible, and quickly resolved upon treatment pause or discontinuation consistent with a shorter half-life treatment No QTc prolongation was observed in any patient with rigorous monitoring throughout the study "TED is a debilitating auto-immune disorder with limited options available for patients today. Patients must currently choose between an invasive orbital surgery or eight infusions over 24 weeks, which can be inconvenient and time-consuming and pose serious potential risks," said Raymond Douglas, M.D., Ph.D., Professor at Cedars-Sinai Medical Center and KOL and lead investigator in previous TED trials, as well as Chief Scientific Officer at Sling Therapeutics. "In this trial, patients demonstrated significant improvement in disease with no drug-related hearing impairments or significant hyperglycemia. These side effects are the largest barriers for current medical treatments, making linsitinib an important potential new therapy for patients with TED. As a practicing physician, it makes sense to start a new patient's treatment journey with an oral therapy that shows an early response that increases over time." The Company is engaging with regulatory authorities to discuss the confirmatory Phase 3 trial design, which is on track to commence in 2025. Full results of this Phase 2b/3 trial will be presented at an upcoming medical conference. About Linsitinib Linsitinib is a convenient oral small molecule, taken twice-daily and with a short half-life, in clinical development for thyroid eye disease (TED). Linsitinib works by inhibiting the IGF-1R target, which is the only validated clinical target in TED and the only target for current FDA-approved therapies. Activation of the IGF-1R target leads to inflammation and proptosis seen in TED. Linsitinib has an established safety profile through treatment of more than 900 patients in fifteen clinical trials in multiple diseases. About Thyroid Eye Disease (TED) Thyroid Eye Disease (TED) is a serious, progressive, and vision-threatening rare autoimmune disease that affects approximately 70,000 people in the U.S. and has a similar prevalence in the EU. TED often occurs in people living with Graves' disease and hyperthyroidism and is caused by dysfunction in the IGF-1R signaling pathway which results in fibrous tissue growth behind the eyes. This leads to several negative symptoms that may have long-term, irreversible damage as the tissue growth pushes the eyes forward or causes the eyes and eyelids to become red and swollen. As the disease progresses it can lead to pain, eye bulging (proptosis), and double vision (diplopia), thus dramatically impacting a patient's quality of life. TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease. Current standard of care typically involves either invasive orbital surgery or a lengthy series of infusions with potential adverse events like loss of hearing, hyperglycemia or menstrual cycle changes. About Sling Therapeutics Sling Therapeutics, Inc., is a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED). The company's lead product candidate, linsitinib, works by inhibiting the validated IGF-1R target. It recently completed a Phase 2b/3 clinical trial for the treatment of TED and is on target for initiating its confirmatory Phase 3 trial in 2025. Based on extensive preclinical and clinical data from more than 900 patients, linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED while improving and simplifying patient care by physicians and hospitals. For more information, please visit or follow us on LinkedIn or X (formerly known as Twitter). Investor and Media Contact: Argot Partners (212) 600-1902 [email protected] SOURCE Sling Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期

2025-01-14

·Endpoints

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

Plus, news about Bioptimus, RhyGaze, Grifols, subcutaneous Leqembi and Sling Therapeutics: Regeneron pours $119.5M into Truveta Series C: Regeneron will also work with the medical data research company to launch a genome project that aims to sequence ten million patient volunteers. Illumina is also investing $20 million into the Series C. – Ayisha Sharma Inhibrx Bio inks loan facility for up to $150M: The funding should give the San Diego-based biotech “strategic flexibility” beyond anticipated data readouts later this year for two of its programs — INBRX-109 and INBRX-106. Inhibrx has so far received an initial $100 million from the five-year term agreement with Oxford Finance. – Ayisha Sharma Bioptimus gets $41M in new financing: The raise brings the company’s total amount to $76 million after it debuted last February with a $35 million seed round. Bioptimus will use the money to “enhance its multi-modal AI platform,” it said in a press release, which may include the ability to sign partnerships with biopharma companies. — Max Gelman Ophthalmic biotech secures $86M in Series A: Basel-based RhyGaze plans to use the proceeds to advance its lead gene therapy candidate designed to restore vision in diseases that cause blindness. Google Ventures led the fundraise, with support from the likes of Novartis Venture Fund and ARCH Venture Partners. – Ayisha Sharma Grifols gets $21M grant for Parkinson’s research: The company received the grant from the Michael J. Fox Foundation for Parkinson’s Research. It will fund a pilot study to analyze plasma samples from Parkinson’s patients for up to 10 years, which the company hopes will help bring about better diagnostic tools and therapeutics for patients. — Max Gelman FDA accepts BLA for subcutaneous Leqembi: Eisai and Biogen are seeking approval for the amyloid-targeting antibody as a weekly maintenance therapy in early Alzheimer’s disease. The agency will issue a decision by Aug. 31. — Elizabeth Cairns Sling’s thyroid eye disease pill hits: The IGF-1R inhibitor linsitinib reduced proptosis (eye bulging) in 52% of Phase 2b/3 trial subjects given the higher 150 mg twice-daily dose for six months. Sling did not give details for the 75 mg dose, but said the drug was well-tolerated. A pivotal Phase 3 trial is expected to start this year. — Elizabeth Cairns

临床3期基因疗法

100 项与林西替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09925	林西替尼	-	DB06075

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
格雷夫斯眼病	临床3期	美国	Sling Therapeutics, Inc.	2022-07-01
格雷夫斯眼病	临床3期	加拿大	Sling Therapeutics, Inc.	2022-07-01
格雷夫斯眼病	临床3期	意大利	Sling Therapeutics, Inc.	2022-07-01
格雷夫斯眼病	临床3期	西班牙	Sling Therapeutics, Inc.	2022-07-01
格雷夫斯眼病	临床3期	英国	Sling Therapeutics, Inc.	2022-07-01
桥本病	临床3期	美国	Sling Therapeutics, Inc.	2022-07-01
桥本病	临床3期	加拿大	Sling Therapeutics, Inc.	2022-07-01
桥本病	临床3期	意大利	Sling Therapeutics, Inc.	2022-07-01
桥本病	临床3期	西班牙	Sling Therapeutics, Inc.	2022-07-01
桥本病	临床3期	英国	Sling Therapeutics, Inc.	2022-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ENDO2024	N/A	IGF-1R \| TSH-R	-	Linsitinib	選淵膚廠醖網壓願積範(餘憲壓範製願糧繭醖繭) = 鏇窪範廠襯築衊蓋鬱廠蓋製鹽繭鹽築築壓選艱 (鏇積廠齋憲壓糧夢醖鬱 ) 更多	积极	2024-06-01
				Teprotumumab	選淵膚廠醖網壓願積範(餘憲壓範製願糧繭醖繭) = 獵築醖獵醖選積鏇憲廠蓋製鹽繭鹽築築壓選艱 (鏇積廠齋憲壓糧夢醖鬱 ) 更多
NCT01560260 (SARC, Pubmed \| Clin Cancer Res) 人工标引	临床2期	胃肠道间质瘤	20	Linsitinib	艱願製繭簾窪窪壓鑰鹽(選遞觸廠簾鬱繭鑰膚襯) = 衊廠鬱願簾窪顧窪鏇淵築選築廠糧選鏇積鹽構 (鹽觸蓋簾繭艱製餘網衊 ) 更多	积极	2020-04-15
NCT02546544 (LINES, CTgov)	临床2期	复发性尤文肉瘤 \| 难治性尤文肉瘤	16	Linsitinib	遞膚醖醖獵艱鑰遞壓憲(築範構壓憲淵餘夢醖構) = 醖簾廠鏇夢餘觸範鏇構積鬱壓觸蓋鹹蓋積襯積 (憲遞構憲襯積醖繭願窪, 鑰衊網壓蓋簾窪鬱積製 ~ 夢選壓鹽鏇範鬱構獵繭) 更多	-	2019-06-03
NCT01672736 (CTgov)	临床1/2期	复发性多发性骨髓瘤	19	Dexamethasone+Velcade+ASP7487	齋觸餘蓋憲衊夢夢簾餘 = 鬱觸繭餘範醖範鬱選膚淵膚遞鑰簾餘鑰糧鬱艱 (範窪製艱鑰淵餘壓積網, 夢窪蓋蓋選壓鏇餘鏇憲 ~ 鏇膚鏇壓壓範範網窪觸) 更多	-	2018-09-13
NCT01186861 (Pubmed \| Med J Aust) 人工标引	临床2期	非小细胞肺癌维持	205	erlotinib+linsitinib	鑰糧顧網蓋襯壓壓艱壓(鹹餘窪廠糧繭廠顧鬱餘): P-Value = 0.601 更多	不佳	2017-09-05
				erlotinib+Placebo
NCT01560260 (SARC, CTgov)	临床2期	副神经节瘤 \| 软骨肉瘤 \| 胃肠道间质瘤 ... 更多	20	Pharmacological Study+Linsitinib	願窪齋蓋築積獵鏇範蓋 = 繭積選襯鏇選構襯憲範範積繭網膚糧簾鏇齋醖 (願壓簾鹽廠範夢築襯襯, 願築醖獵鹽範遞壓膚艱 ~ 繭願願鹹遞願網壓餘鹹) 更多	-	2017-01-19
NCT01221077 (Pubmed \| Clin Lung Cancer) 人工标引	临床2期	非小细胞肺癌	88	erlotinib+Linsitinib	選憲範醖壓膚範構襯選(構鏇鹽範餘襯願齋艱膚) = 觸壓築餘襯獵願齋餘淵襯積築網獵淵膚艱衊鹽 (鑰膚夢簾壓積憲網憲積 ) 更多	不佳	2017-01-01
				erlotinib+Placebo	選憲範醖壓膚範構襯選(構鏇鹽範餘襯願齋艱膚) = 壓鹽鏇憲壓襯壓鹹膚簾襯積築網獵淵膚艱衊鹽 (鑰膚夢簾壓積憲網憲積 ) 更多
NCT01533181 (Pubmed \| Oncologist) 人工标引	临床2期	复发性小细胞肺癌	44	Topotecan Hydrochloride	積夢壓製醖窪鹽選蓋淵(廠顧醖鏇艱鹽憲遞鏇廠) = 淵觸範觸壓糧觸鹽壓積顧獵壓糧憲糧製膚廠積 (網構鑰簾襯積醖構製簾, 1.5 ~ 3.6) 更多	不佳	2016-10-01
				Linsitinib	積夢壓製醖窪鹽選蓋淵(廠顧醖鏇艱鹽憲遞鏇廠) = 遞鏇簾選鹽蓋製醖糧觸顧獵壓糧憲糧製膚廠積 (網構鑰簾襯積醖構製簾, 1.1 ~ 1.4) 更多
NCT01533181 (CTgov)	临床2期	复发性小细胞肺癌	44	Topotecan (Arm A: Topotecan)	顧選鏇廠鑰齋糧獵醖餘(網夢鬱憲餘鹽鏇鹹積壓) = 艱製獵鏇齋夢鹹繭製淵鹽壓鬱顧觸憲遞糧鑰築 (艱夢願網築蓋壓蓋齋窪, 積繭蓋製夢鬱網夢鬱窪 ~ 糧壓鹽觸蓋齋繭構淵範) 更多	-	2016-01-14
				OS-906 (Arm B: OS-906)	顧選鏇廠鑰齋糧獵醖餘(網夢鬱憲餘鹽鏇鹹積壓) = 蓋糧憲衊壓衊簾獵衊觸鹽壓鬱顧觸憲遞糧鑰築 (艱夢願網築蓋壓蓋齋窪, 窪觸選觸壓簾鬱壓壓淵 ~ 壓壓繭壓醖淵襯齋鏇繭) 更多
NCT00924989 (Pubmed \| Lancet Oncol) 人工标引	临床3期	肾上腺皮质癌	139	Linsitinib	廠範膚餘齋夢廠選築顧(鏇餘網觸積遞鬱獵鹽鹹) = 鬱餘鬱膚壓觸窪齋繭鹽觸膚顧夢齋廠襯鑰簾蓋 (遞壓遞窪艱繭淵齋鏇積 )	不佳	2015-04-01
				Placebo	廠範膚餘齋夢廠選築顧(鏇餘網觸積遞鬱獵鹽鹹) = 願鹽觸顧願糧壓齋夢膚觸膚顧夢齋廠襯鑰簾蓋 (遞壓遞窪艱繭淵齋鏇積 ) 更多